Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mol Nutr Food Res. 2019 Dec 11;64(1):e1900633. doi: 10.1002/mnfr.201900633

Figure 1: Treatment with resveratrol reduces clinical parameters in TNBS-induced colitis.

Figure 1:

BALB/c mice were injected intrarectally with 1mg of TNBS to induce colitis. Mice treated with resveratrol were given 100mg/kg in vehicle (1% CMC) by oral gavage 24 hours prior to the TNBS injection as well as daily up until the experimental end point (day 4). Experimental groups consisted of: Vehicle (n=5), Resveratrol (n=5), TNBS+Veh (n=5), and TNBS+Res (n=5). Initial clinical parameters consisted of evaluating weight (A), percent weight loss (B) and colon length (C-D). (E) Representative colonoscopies are shown from experimental groups during peak of disease (day 3). (F) Representative colon sections from fixed and paraffin-embedded tissue sections stained with H&E at 20x objective. Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way ANOVA and post-hoc Tukey’s test for bar graphs and Mann-Whitney test for weight data. Data are representative of at least 3 independent experiments.